ET Pharma
Sep 1, 2026, 12:16 PM
Cipla licenses cancer bispecific from China’s Sino Biopharma
Under the agreement, the chinese drugmaker is entitled to receive up to $123 million in upfront, development and regulatory milestone along with double-digit royalties on annual sales.
Read more



